This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ADVANCE was a phase 3 randomized parallel-group treatment trial evaluating dolutegravir-based first-line antiretroviral therapy combinations for HIV-1 infection.
| Feature | ADVANCE |
|---|---|
| NCT ID | NCT03122262 |
| Phase | Phase 3 |
| Status | COMPLETED |
| Condition | HIV-1 Infection |
| Design | Randomized, parallel, open-label treatment study |
| Primary purpose | TREATMENT |
2. Clinical Question
Population
Participants with HIV-1 infection enrolled in a first-line antiretroviral therapy study.
Interventions
Dolutegravir (DTG), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), Truvada, and Atripla-based regimens.
Comparator
The study included three randomized treatment groups.
Primary question
What proportion of patients achieved undetectable plasma HIV-1 RNA levels at Week 48 in each treatment group?
3. Trial Design
Randomized
None
Parallel
OTHER
Treatment groups
| Group | Regimen |
|---|---|
| Arm 1 | DTG + TAF + FTC |
| Arm 2 | DTG + TDF + FTC |
| Arm 3 | EFV + TDF + FTC |
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| Primary endpoint | Proportion of patients with undetectable plasma HIV-1 RNA levels (< 50 copies/mL) at Week 48 | 48 weeks |
5. Planned Analysis
The ClinicalTrials.gov record identifies the primary endpoint as the proportion of participants with undetectable plasma HIV-1 RNA levels at Week 48. The proportion would typically be summarized separately for each randomized treatment group.
The registry does not report posted statistical analyses or outcome estimates for this endpoint.
6. Statistical Methodology
Binary endpoint analysis
The primary endpoint is a binary virologic outcome: whether plasma HIV-1 RNA is below the prespecified threshold of 50 copies/mL at Week 48. Binary outcomes are commonly summarized using proportions and compared between randomized groups using methods appropriate for the study design.
Response rate = number of participants meeting endpoint ÷ number of participants evaluated
Randomization and treatment comparison
Randomization creates the framework for comparing treatment groups because treatment assignment is determined independently of participant characteristics. In a randomized trial, comparisons of endpoint proportions are interpreted as comparisons among the assigned treatment strategies.
7. Statistical Methods Explained
Why is the primary endpoint a proportion?
The endpoint measures the fraction of participants achieving a virologic threshold at a defined time point. This directly summarizes the percentage of participants meeting the treatment goal at Week 48.
What does an undetectable HIV-1 RNA result represent statistically?
It represents a binary classification for each participant. The analysis compares how frequently this outcome occurs across randomized treatment groups.
Why does randomization matter?
Randomization helps balance known and unknown factors between groups, allowing differences in outcomes to be interpreted within the framework of the assigned treatments.
Why might confidence intervals be important?
A confidence interval describes uncertainty around an estimated treatment-group difference or ratio. It provides information about statistical precision beyond the point estimate alone.
Why should treatment groups not be compared using percentages alone?
Observed proportions describe outcomes, but formal comparisons account for sampling variability and the randomized design.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses or endpoint results.
- The registry record does not report subgroup analyses, safety event summaries by treatment arm, or additional efficacy analyses.
- The primary endpoint is measured at a single time point, so interpretation depends on the prespecified Week 48 assessment.
- Open-label design may introduce differences in treatment experience or reporting behavior, although the impact depends on the endpoint and analysis methods.
9. Why This Trial Matters Statistically
| Concept | Application in ADVANCE |
|---|---|
| Randomization | Three-arm randomized treatment comparison |
| Parallel design | Participants are assigned to separate treatment strategies |
| Binary endpoint | Virologic suppression defined by HIV-1 RNA threshold |
| Clinical trial estimation | Group-specific proportions summarize endpoint achievement |